Charalambos (Babis) Andreadis, MD, MSCE
Professor of Clinical Medicine, Department of Medicine, UCSF; Director, Baszucki Lymphoma Therapeutic Initiative, UCSF
Research Summary
I am an experienced hematologist in a comprehensive cancer center with clinical and research expertise in hematologic malignancies, cell therapies and stem cell transplantation. I have extensive clinical and research training in these areas and in genetic pharmacoepidemiology, in which I hold a Master’s degree. I have conducted and consulted on numerous clinical research endeavors in patients with hematologic malignancies, and I am currently the Director of the Baszucki Lymphoma Therapeutic Initiative and the hematology clinical research co-chair at UCSF. I have collaborated with colleagues across departments and institutions (BMT-CTN and ALLIANCE) to conduct studies and perform data analysis on several aspects and phases of therapy for these patients. My personal area of interest involves the identification and characterization of genetic determinants of response to and toxicity from cancer therapy.
Education
Oberlin College, Oberlin, OH, BA, 1993, Cum Laude, Biochemistry
College of Physicians & Surgeons, Columbia University, New York, NY, MD, 1998, Medicine
University of Pennsylvania, Philadelphia, PA, MSCE, 2005, Pharmacogenetics/Epidemiology
Honors & Awards
- 1992
Phi Beta Kappa, Z of Ohio - 1993
Departmental honors and Cum Laude, Oberlin College - 1994 - 1998
Nicholplus Interschool Fellowship, Columbia University - 1995
McGraw-Hill Publishers Award, Columbia University - 1996
Grove memorial Scholarship, Columbia University - 1997
Alpha Omega Alpha, A of New York - 1998
The Endocrine Society Medical Student Achievement Award - 2004
Pharmacoepidemiology Training Award, University of Pennsylvania - 2012
Hematology Teaching Award, Department of Medicine, UCSF - 2013
Marc A. Shuman Mentoring Award, Division of Hematology/Oncology - 2015
Bay Area Man of the Year, Leukemia & Lymphoma Society
Selected Publications
- Wang VE, Blaser BW, Patel RK, Behbehani GK, Rao AA, Durbin-Johnson B, Jiang T, Logan AC, Settles M, Mannis GN, Olin R, Damon LE, Martin TG, Sayre PH, Gaensler KM, McMahon E, Flanders M, Weinberg V, Ye CJ, Carbone DP, Munster PN, Fragiadakis GK, McCormick F, Andreadis C. Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis. Blood Cancer Discov. 2021 09; 2(5):434-449. View on PubMed
- Kambhampati S, Fakhri B, Ai WZ, Kaplan LD, Tuscano JM, Wieduwilt MJ, Sudhindra A, Cavallone E, Reiner J, Aoun C, Castillo M, Martinelli M, Ta T, Le D, Padilla M, Crawford E, Andreadis CB. Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial. Clin Lymphoma Myeloma Leuk. 2021 03; 21(3):139-146. View on PubMed
- Thiruvengadam SK, Hunter B, Varnavski A, Fakhri B, Kaplan L, Ai WZ, Pampaloni M, Huang CY, Martin T, Damon L, Andreadis CB. Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk. 2021 04; 21(4):246-256.e2. View on PubMed
- Nawas MT, Sheng Y, Huang CY, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannis GN, Logan AC, Damon LE, Olin RL. Serial comprehensive geriatric and quality of life assessments in adults age ≥ 50 years undergoing autologous hematopoietic cell transplantation. J Geriatr Oncol. 2021 05; 12(4):531-539. View on PubMed